CN103183604A - Preparation method of vedaprofen - Google Patents
Preparation method of vedaprofen Download PDFInfo
- Publication number
- CN103183604A CN103183604A CN2011104485722A CN201110448572A CN103183604A CN 103183604 A CN103183604 A CN 103183604A CN 2011104485722 A CN2011104485722 A CN 2011104485722A CN 201110448572 A CN201110448572 A CN 201110448572A CN 103183604 A CN103183604 A CN 103183604A
- Authority
- CN
- China
- Prior art keywords
- reaction
- compound
- acid
- catalyst
- molar ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 9
- VZUGVMQFWFVFBX-UHFFFAOYSA-N 2-(4-cyclohexyl-1-naphthyl)propanoic acid Chemical compound C12=CC=CC=C2C(C(C(O)=O)C)=CC=C1C1CCCCC1 VZUGVMQFWFVFBX-UHFFFAOYSA-N 0.000 title description 4
- 229950010082 vedaprofen Drugs 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims abstract description 80
- 238000000034 method Methods 0.000 claims abstract description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 229940126214 compound 3 Drugs 0.000 claims description 10
- 229940125898 compound 5 Drugs 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002841 Lewis acid Substances 0.000 claims description 8
- 150000007517 lewis acids Chemical class 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000008096 xylene Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 238000005907 ketalization reaction Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- JEQDSBVHLKBEIZ-REOHCLBHSA-N (2s)-2-chloropropanoyl chloride Chemical group C[C@H](Cl)C(Cl)=O JEQDSBVHLKBEIZ-REOHCLBHSA-N 0.000 claims description 3
- KQGXQUZDMSFMNG-UHFFFAOYSA-N 2-bromopropanoyl 2-bromopropanoate Chemical compound CC(Br)C(=O)OC(=O)C(C)Br KQGXQUZDMSFMNG-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- OZGMODDEIHYPRY-UHFFFAOYSA-N 2-bromopropanoyl chloride Chemical compound CC(Br)C(Cl)=O OZGMODDEIHYPRY-UHFFFAOYSA-N 0.000 claims description 2
- OAVBKHDCXXETQR-UHFFFAOYSA-N 2-chloropropanoyl 2-chloropropanoate Chemical compound CC(Cl)C(=O)OC(=O)C(C)Cl OAVBKHDCXXETQR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 claims description 2
- 238000007171 acid catalysis Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 238000006462 rearrangement reaction Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000009776 industrial production Methods 0.000 abstract description 3
- 238000005580 one pot reaction Methods 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 239000012043 crude product Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- -1 2-(4-cyclohexylnaphthyl) propanecyanide Chemical compound 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- RAYZALBEMJMGEA-UHFFFAOYSA-N 1-cyclohexylnaphthalene Chemical compound C1CCCCC1C1=CC=CC2=CC=CC=C12 RAYZALBEMJMGEA-UHFFFAOYSA-N 0.000 description 5
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- NEPRLVQUHMDNAF-UHFFFAOYSA-N 2-(1-chloroethyl)-2-(4-cyclohexylnaphthalen-1-yl)-5,5-dimethyl-1,3-dioxane Chemical compound CC(Cl)C1(OCC(C)(C)CO1)c1ccc(C2CCCCC2)c2ccccc12 NEPRLVQUHMDNAF-UHFFFAOYSA-N 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- YCBGZXAJACCOAD-UHFFFAOYSA-N 1-(chloromethyl)-4-cyclohexylnaphthalene Chemical compound C12=CC=CC=C2C(CCl)=CC=C1C1CCCCC1 YCBGZXAJACCOAD-UHFFFAOYSA-N 0.000 description 1
- BPXITDRZRADOHD-UHFFFAOYSA-N 2-(4-cyclohexylnaphthalen-1-yl)acetic acid Chemical compound C12=CC=CC=C2C(CC(=O)O)=CC=C1C1CCCCC1 BPXITDRZRADOHD-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- FRCJSXDEUDNZIB-UHFFFAOYSA-N CC(=O)C1=CC=C(C2=CC=CC=C21)C3CCCCC3 Chemical compound CC(=O)C1=CC=C(C2=CC=CC=C21)C3CCCCC3 FRCJSXDEUDNZIB-UHFFFAOYSA-N 0.000 description 1
- CPVOZGSWKYIHPY-UHFFFAOYSA-N CCC.[C-]#N Chemical compound CCC.[C-]#N CPVOZGSWKYIHPY-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007265 chloromethylation reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及维达洛芬的制备方法。本发明提供的方法只有四步反应,所需原料都是常规原料,而且该方法易于操作,所有步骤均可以采用”一锅法”进行,便于工业化生产。 The invention relates to a preparation method of vidaprofen. The method provided by the invention has only four steps of reaction, the required raw materials are all conventional raw materials, and the method is easy to operate, and all steps can be carried out by "one-pot method", which is convenient for industrial production.
Description
技术领域 technical field
本发明涉及一种维达洛芬的制备方法。The invention relates to a preparation method of vidaprofen.
背景技术 Background technique
如下结构式1所示的维达洛芬(vedaprofen)是化合物2-(4-环己基萘基)丙酸的通用药品名称。Vidaprofen (vedaprofen) shown in the following structural formula 1 is the generic drug name of the compound 2-(4-cyclohexylnaphthyl)propionic acid.
维达洛芬属于2-芳基丙酸类化合物,是一种用于解热、镇痛的非甾类消炎药,主要应用于痛风、内分泌及代谢类疾病。该化合物有一个手性中心,因此有S(+)和R(-)一对对映异构体。现代药理学研究证明,维达洛芬的S(+)和R(-)构型在对前列腺素(PGF2α)的抑制作用上是完全相同的,因此这两种构型都是优性异构体。维达洛芬的消旋体混合物已经被开发成为马类和犬科类兽药,目前在欧美已经被许可用于狗和马的治疗。因此,合成维达洛芬无需不对称合成或手性拆分,得到消旋体即可。Vidaprofen belongs to 2-arylpropionic acid compounds and is a non-steroidal anti-inflammatory drug used for antipyretic and analgesic. It is mainly used in gout, endocrine and metabolic diseases. The compound has a chiral center and therefore has a pair of enantiomers, S(+) and R(-). Modern pharmacological studies have proved that the S(+) and R(-) configurations of vidaprofen are completely the same in the inhibitory effect on prostaglandins (PGF 2α ), so these two configurations are superior and different. Construct. The racemic mixture of vidaprofen has been developed into equine and canine veterinary drugs, and has been approved for the treatment of dogs and horses in Europe and America. Therefore, there is no need for asymmetric synthesis or chiral resolution to synthesize vidaprofen, only the racemate can be obtained.
通过文献检索,其文献或专利报道的主要合成路线和方法有如下两种:Through literature search, the main synthetic routes and methods reported in the literature or patents are as follows:
例如,美国专利US4218473公开了一种维达洛芬的制备方法,反应式如下:For example, U.S. Patent US4218473 discloses a kind of preparation method of vidaprofen, and reaction formula is as follows:
以1-环己基萘(可以参照文献Journal of the American Chemical Society,2004,126(12),3686-3687制备而得)为起始原料,首先与甲醛、浓盐酸进行氯甲基化反应得到1-氯甲基-4-环己基萘;得到的氯甲基化中间体用氰化钠氰基化,再水解氰基得到中间体4-环己基-1-萘乙酸;得到的酸中间体用甲醇酯化成相应甲酯,再用碘甲烷在α位甲基化,得到2-(4-环己基萘基)丙酸甲酯;该甲酯通过碱性条件水解并用盐酸酸化得到维达洛芬。Taking 1-cyclohexylnaphthalene (which can be prepared with reference to the document Journal of the American Chemical Society, 2004, 126 (12), 3686-3687) as a starting material, firstly carry out chloromethylation reaction with formaldehyde and concentrated hydrochloric acid to obtain 1 -Chloromethyl-4-cyclohexylnaphthalene; The obtained chloromethylated intermediate is cyanated with sodium cyanide, and then the cyano group is hydrolyzed to obtain the intermediate 4-cyclohexyl-1-naphthalene acetic acid; The acid intermediate obtained is used Methanol is esterified to the corresponding methyl ester, and methylated at the α position with methyl iodide to obtain methyl 2-(4-cyclohexylnaphthyl) propionate; the methyl ester is hydrolyzed under alkaline conditions and acidified with hydrochloric acid to obtain Vidaprofen .
该路线需用氰化钠和碘甲烷等剧毒管制品,大规模生产时极大威胁操作人员的人身健康和安全。另外,这种方法路线较长,步骤较多,含6步反应,生产成本较高。This route requires the use of highly toxic controlled products such as sodium cyanide and methyl iodide, which greatly threaten the personal health and safety of operators in large-scale production. In addition, this method has a long route and many steps, including 6-step reactions, and the production cost is relatively high.
根据文献【Journal of medicinal chemistry,2007,50(12),2787-2798和Tetrahedron,1995,51(46),12583-12590】,也可以得到一种维达洛芬的制备方法,反应式如下:According to the literature [Journal of medicinal chemistry, 2007, 50 (12), 2787-2798 and Tetrahedron, 1995, 51 (46), 12583-12590], a preparation method of vidaprofen can also be obtained, and the reaction formula is as follows:
以1-环己基萘为起始原料,首先与乙酰氯进行氯乙酰化反应得到1-乙酰基-4-环己基萘;得到的乙酰化中间体经过硼氢化钠还原成醇、羟基氯化和氰化钠的氰基取代,得到2-(4-环己基萘基)丙氰;该丙氰中间体通过水解得到维达洛芬。Using 1-cyclohexylnaphthalene as the starting material, firstly carry out chloroacetylation reaction with acetyl chloride to obtain 1-acetyl-4-cyclohexylnaphthalene; the obtained acetylated intermediate is reduced to alcohol, hydroxyl chloride and The cyano group of sodium cyanide is substituted to obtain 2-(4-cyclohexylnaphthyl) propanecyanide; the intermediate of propanecyanide is hydrolyzed to obtain vidaprofen.
该路线的缺点仍然是需用氰化钠等剧毒管制品,反应危险性高、操作难度大,而且还需要5步反应。The disadvantage of this route is still the need to use highly toxic control products such as sodium cyanide, high reaction risk, difficult operation, and 5-step reaction.
发明内容 Contents of the invention
针对上述问题,本发明的目的是提供一种制备化合物2-(4-环己基萘基)丙酸的新制备方法。该方法只有四步反应,步骤较短,所需原料都是常规原料,避免了剧毒品氰化钠或者氰化钾的使用。而且该路线所有步骤可以采用”一锅法”进行,且产品质量稳定,便于工业化生产。因此,该工艺易于操作,便于工业化生产。For the problems referred to above, the purpose of this invention is to provide a kind of new preparation method for preparing compound 2-(4-cyclohexylnaphthyl) propionic acid. The method has only four reaction steps, and the steps are relatively short, and the required raw materials are conventional raw materials, thereby avoiding the use of highly toxic sodium cyanide or potassium cyanide. Moreover, all steps of this route can be carried out by "one pot method", and the product quality is stable, which is convenient for industrial production. Therefore, the process is easy to operate and convenient for industrial production.
为了达到上述目的,本发明采用以下技术方案来实现。In order to achieve the above object, the present invention adopts the following technical solutions to achieve.
本发明的维达洛芬的制备方法,包括以下步骤:The preparation method of Vidaprofen of the present invention may further comprise the steps:
A)1-环己基萘(即化合物2)与2-卤代丙酰化试剂进行付-克酰化反应,得到化合物3,其反应式如下:A) 1-cyclohexylnaphthalene (i.e. compound 2) and 2-halopropionylating reagents carry out Friedel-Crafts acylation reaction to obtain compound 3, and its reaction formula is as follows:
B)化合物3用二元醇进行缩酮化保护,得到化合物4,其反应式如下:B) Compound 3 is protected by ketalization with a dihydric alcohol to obtain compound 4, the reaction formula of which is as follows:
C)化合物4在路易斯酸催化下进行芳基迁移重排,得到化合物5,其反应式如下:C) Compound 4 undergoes aryl migration rearrangement under Lewis acid catalysis to obtain compound 5, the reaction formula of which is as follows:
D)化合物5经过水解,得到维达洛芬(即化合物1),其反应式如下:D) compound 5 is hydrolyzed to obtain vidaprofen (i.e. compound 1), and its reaction formula is as follows:
其中,X为氟、氯、溴或碘,Wherein, X is fluorine, chlorine, bromine or iodine,
各R独立地为氢、甲基或乙基,each R is independently hydrogen, methyl or ethyl,
n为0、1或2;n is 0, 1 or 2;
优选地,Preferably,
X为氯或溴,X is chlorine or bromine,
各R独立地为氢或甲基,each R is independently hydrogen or methyl,
n为0或1。n is 0 or 1.
下面更详细地描述本发明的制备方法:Describe the preparation method of the present invention in more detail below:
在所述步骤A)中:In said step A):
所述2-卤代丙酰化试剂可以为2-氯丙酰氯、2-氯丙酸酐、2-溴丙酰氯或2-溴丙酸酐等;一般2-卤代丙酰化试剂与化合物2的摩尔比为1.5∶1~1∶1,并优选1.1∶1。The 2-halopropionylating reagent can be 2-chloropropionyl chloride, 2-chloropropionic anhydride, 2-bromopropionyl chloride or 2-bromopropionic anhydride, etc.; general 2-halogenating propionylating reagent and compound 2 The molar ratio is 1.5:1 to 1:1, and preferably 1.1:1.
反应使用Lewis酸作为催化剂,所述Lewis酸可为选自AlCl3、ZnCl2、BF3和TiCl4中的一种或多种,且Lewis酸与化合物2的摩尔比为2∶1~1∶1,并优选1.2∶1。其反应机理为:Lewis酸与酰氯或酸酐结合,形成的羰基正离子可以与芳环上的碳负离子结合形成碳-碳键的结构。The reaction uses a Lewis acid as a catalyst, and the Lewis acid can be one or more selected from AlCl 3 , ZnCl 2 , BF 3 and TiCl 4 , and the molar ratio of Lewis acid to compound 2 is 2:1 to 1: 1, and preferably 1.2:1. The reaction mechanism is: Lewis acid is combined with acid chloride or acid anhydride, and the carbonyl cation formed can combine with the carbanion on the aromatic ring to form a carbon-carbon bond structure.
此反应使用的溶剂可以是二氯甲烷、氯仿、1,2-二氯乙烷或氯苯等。The solvent used in this reaction can be dichloromethane, chloroform, 1,2-dichloroethane or chlorobenzene and the like.
此反应合适的温度范围为-78℃~30℃,并优选-10℃~0℃。A suitable temperature range for this reaction is -78°C to 30°C, and preferably -10°C to 0°C.
反应完成后,采用淬灭剂淬灭反应,再用有机溶剂进行提取,然后对提取得到的有机相进行减压浓缩,制得化合物3粗品,化合物3粗品无需纯化可以直接用于下一步反应。其中,所述淬灭剂可为选自水、盐酸、硫酸、甲酸、乙酸、丙酸、丁酸、草酸和柠檬酸中的一种或多种;提取所使用的有机溶剂为乙酸乙酯、甲苯、二氯甲烷或甲基叔丁基醚等。After the reaction is completed, quench the reaction with a quencher, then extract with an organic solvent, and then concentrate the extracted organic phase under reduced pressure to obtain a crude compound 3, which can be directly used in the next step without purification. Wherein, the quenching agent can be selected from one or more of water, hydrochloric acid, sulfuric acid, formic acid, acetic acid, propionic acid, butyric acid, oxalic acid and citric acid; the organic solvent used for extraction is ethyl acetate, Toluene, dichloromethane or methyl tert-butyl ether, etc.
在所述步骤B)中:In said step B):
用二元醇对化合物3上的羰基进行缩酮化保护,所述二元醇可以为乙二醇、1,3丙二醇、新戊二醇等;一般二元醇试剂与化合物3的摩尔比为3∶1~1∶1,并优选1.5∶1。Carry out ketalization protection to the carbonyl on compound 3 with dibasic alcohol, described dibasic alcohol can be ethylene glycol, 1,3 propanediol, neopentyl glycol etc.; The molar ratio of general dibasic alcohol reagent and compound 3 is 3:1 to 1:1, and preferably 1.5:1.
缩酮化反应所用的催化剂为选自硫酸、醋酸、对甲苯磺酸、甲磺酸、柠檬酸中的一种或多种;且一般酸催化剂与化合物3的摩尔比为0∶1~1∶1,并优选0.1∶1。The catalyst used in the ketalization reaction is one or more selected from sulfuric acid, acetic acid, p-toluenesulfonic acid, methanesulfonic acid, citric acid; and the molar ratio of the general acid catalyst to compound 3 is 0:1~1: 1, and preferably 0.1:1.
此反应使用的溶剂可以是苯、甲苯、二甲苯或氯苯等。反应过程中需要用分水器或其他除水装置或除水试剂将反应生成的水分及时分离除去。The solvent used in this reaction can be benzene, toluene, xylene or chlorobenzene and the like. During the reaction, it is necessary to use a water separator or other water removal devices or water removal reagents to separate and remove the water generated by the reaction in time.
该反应完成后,反应液采用水为淬灭剂来淬灭反应;有机相用水和食盐水洗涤后减压浓缩,得到化合物4粗品,化合物4的粗品无需纯化可以直接用于下一步反应。After the reaction was completed, the reaction solution was quenched with water as a quencher; the organic phase was washed with water and brine and then concentrated under reduced pressure to obtain a crude compound 4, which could be directly used in the next step without purification.
在所述步骤C)中:In said step C):
化合物4的芳基迁移重排反应使用的催化剂为选自ZnO、ZnCl2和Zn(OAc)2中的一种或多种,且催化剂与化合物4的摩尔比为0∶1~3∶1,并优选0.2∶1。其反应机理为:在锌试剂的催化下,芳基从缩酮碳上迁移至邻位的卤素原子所在碳上,同时卤素原子与锌试剂结合离去,形成化合物5的酯基结构。The catalyst used in the aryl transfer rearrangement reaction of compound 4 is one or more selected from ZnO, ZnCl 2 and Zn(OAc) 2 , and the molar ratio of catalyst to compound 4 is 0:1~3:1, And preferably 0.2:1. The reaction mechanism is: under the catalysis of the zinc reagent, the aryl group migrates from the ketal carbon to the carbon of the adjacent halogen atom, and at the same time the halogen atom combines with the zinc reagent to form the ester group structure of compound 5.
此反应使用的溶剂可以是甲苯、二甲苯或氯苯等。The solvent used in this reaction can be toluene, xylene or chlorobenzene and the like.
此反应合适的温度范围为80℃~160℃,并优选110℃~130℃。A suitable temperature range for this reaction is 80°C to 160°C, and preferably 110°C to 130°C.
该反应完成后,采用淬灭剂淬灭反应,反应有机相用水和食盐水洗涤后减压浓缩,制得化合物5粗品,化合物5粗品无需纯化可以直接用于下一步反应。其中,淬灭剂可为选自盐酸、硫酸、甲酸、乙酸和柠檬酸中的一种或多种。After the reaction was completed, the reaction was quenched with a quencher, the organic phase of the reaction was washed with water and brine, and then concentrated under reduced pressure to obtain a crude compound 5, which could be directly used in the next reaction without purification. Wherein, the quenching agent may be one or more selected from hydrochloric acid, sulfuric acid, formic acid, acetic acid and citric acid.
在所述步骤D)中:In said step D):
化合物5的水解,可以在碱性条件下,也可以在酸性条件下。水解化合物5所用的碱可以为KOH、NaOH、LiOH、K2CO3、Cs2CO3或Na2CO3等;一般碱与化合物5的摩尔比为5∶1~1∶1,并优选3∶1。水解化合物5所用的酸可以为硫酸、盐酸或对甲苯磺酸等。The hydrolysis of compound 5 can be under basic or acidic conditions. The base used for hydrolyzing compound 5 can be KOH, NaOH, LiOH, K 2 CO 3 , Cs 2 CO 3 or Na 2 CO 3 etc.; generally the molar ratio of base to compound 5 is 5:1 to 1:1, and preferably 3 : 1. The acid used for the hydrolysis of compound 5 can be sulfuric acid, hydrochloric acid or p-toluenesulfonic acid and the like.
本发明的制备方法,共计四步,合成路线短;所需原料都是常规原料,避免使用剧毒的氰化物。该路线中每步均为常规反应,后处理简单,易操作;且反应结束后,反应液经过后处理得到的粗产品无需纯化可以直接用于下一步反应,实现了整条路线“一锅法”进行,便于工业化生产。The preparation method of the present invention has a total of four steps, and the synthesis route is short; the required raw materials are all conventional raw materials, and the use of highly toxic cyanide is avoided. Each step in this route is a conventional reaction, and the post-treatment is simple and easy to operate; and after the reaction, the crude product obtained from the reaction solution after post-treatment can be directly used in the next step without purification, realizing the "one-pot method" of the whole route "Carry out, be convenient to industrialized production.
具体实施方式 Detailed ways
以下实施例进一步地说明本发明的技术方案、本发明的特征和优点,但本发明并不局限于下面的实施例。The following examples further illustrate the technical solutions, features and advantages of the present invention, but the present invention is not limited to the following examples.
1.化合物3的合成1. Synthesis of compound 3
实施例1Example 1
1-(2-氯丙酰基)-4环己基萘的合成Synthesis of 1-(2-chloropropionyl)-4cyclohexylnaphthalene
在N2保护下,于500ml三口瓶中加入AlCl3(22.8g,0.17mol)和二氯甲烷(250mL)并冷却至-10℃~0℃。搅拌下,滴加入2-氯丙酰氯(19.8g,0.157mol)和1-环己基萘(2,30.0g,0.143mol)混合物的二氯甲烷(50mL)溶液,并保持反应温度始终在-10℃~0℃。加完后,继续在-10℃~0℃保持2小时直至反应完全。将反应液倒入300mL稀盐酸(2N)中淬灭反应,搅拌分层并分离出有机层,将有机层用200mL水和200mL饱和食盐水分别洗涤后,减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 , AlCl 3 (22.8 g, 0.17 mol) and dichloromethane (250 mL) were added into a 500 ml three-necked flask and cooled to -10°C to 0°C. Under stirring, a dichloromethane (50 mL) solution of a mixture of 2-chloropropionyl chloride (19.8 g, 0.157 mol) and 1-cyclohexylnaphthalene (2, 30.0 g, 0.143 mol) was added dropwise, and the reaction temperature was kept at -10 ℃~0℃. After the addition, continue to keep at -10°C to 0°C for 2 hours until the reaction is complete. The reaction solution was poured into 300mL of dilute hydrochloric acid (2N) to quench the reaction, the layers were stirred and the organic layer was separated, and the organic layer was washed with 200mL of water and 200mL of saturated brine respectively, and the solvent was evaporated under reduced pressure to obtain a crude product. Brown oily. Crude yield: Quantitative.
粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.
MS(ESI,m/z):[M+]+301.2。MS (ESI, m/z): [M+] + 301.2.
1H-NMR(400MHz,CDCl3):δ8.52(m,1H);8.03(d,1H,J=8.8Hz);7.65~7.92(m,2H);7.42~7.60(m,2H);5.42(m,1H);2.70(m,1H);1.84-2.05(m,4H);1.80(d,3H,J=3.6Hz);1.78(m,1H);1.29-1.59(m,4H);1.31(m,1H)。 1 H-NMR (400MHz, CDCl 3 ): δ8.52(m, 1H); 8.03(d, 1H, J=8.8Hz); 7.65~7.92(m, 2H); 7.42~7.60(m, 2H); 5.42(m, 1H); 2.70(m, 1H); 1.84-2.05(m, 4H); 1.80(d, 3H, J=3.6Hz); 1.78(m, 1H); 1.29-1.59(m, 4H) ; 1.31 (m, 1H).
实施例2Example 2
在N2保护下,于500ml三口瓶中加入TiCl4(32.2g,0.17mol)和氯苯(250mL)并冷却至-10℃~0℃。搅拌下,逐滴加入2-溴丙酸酐(45.2g,0.157mol)和1-环己基萘(30.0g,0.143mol)混合物的氯苯(50mL)溶液,并保持反应温度始终在-10℃~0℃。加完后,继续在10℃~0℃保持2小时直至反应完全。将反应液倒入300mL柠檬酸水溶液(2N)中淬灭反应,搅拌分层并分离出有机层,有机层用200mL水和200mL饱和食盐水洗涤后,减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 , TiCl 4 (32.2 g, 0.17 mol) and chlorobenzene (250 mL) were added into a 500 ml three-necked flask and cooled to -10°C to 0°C. Under stirring, a chlorobenzene (50mL) solution of a mixture of 2-bromopropionic anhydride (45.2g, 0.157mol) and 1-cyclohexylnaphthalene (30.0g, 0.143mol) was added dropwise, and the reaction temperature was kept at -10°C to 0°C. After the addition, continue to keep at 10°C to 0°C for 2 hours until the reaction is complete. Pour the reaction solution into 300mL citric acid aqueous solution (2N) to quench the reaction, stir and separate the layers and separate the organic layer. After the organic layer is washed with 200mL water and 200mL saturated brine, the solvent is evaporated under reduced pressure to obtain a crude product, brown Oily. Crude product yield: Quantitative.
粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.
2.化合物4的合成2. Synthesis of compound 4
实施例3Example 3
2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环的合成Synthesis of 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane
N2气保护下,常温下于500ml三口瓶中加入1-(2-氯丙酰基)-4环己基萘(3,42.9g,0.143mol)和甲苯(430mL)。搅拌下,向反应液中加入新戊二醇(22.3g,0.214mol)和对甲苯磺酸(2.7g,0.014mol)。加毕,在反应瓶上装配分水器,然后加热至回流并保持回流20小时直至反应完全。冷却反应液至室温,加入200mL水淬灭反应,搅拌分离出有机相。有机相用水洗两次(200mL×2)、饱和食盐水(200mL)洗一次,减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 gas, 1-(2-chloropropionyl)-4cyclohexylnaphthalene (3, 42.9g, 0.143mol) and toluene (430mL) were added into a 500ml three-necked flask at room temperature. Under stirring, neopentyl glycol (22.3 g, 0.214 mol) and p-toluenesulfonic acid (2.7 g, 0.014 mol) were added to the reaction liquid. After the addition is complete, install a water separator on the reaction bottle, then heat to reflux and maintain reflux for 20 hours until the reaction is complete. Cool the reaction solution to room temperature, add 200 mL of water to quench the reaction, stir and separate the organic phase. The organic phase was washed twice with water (200 mL×2) and once with saturated brine (200 mL), and the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude product yield: Quantitative.
粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.
MS(ESI,m/z):[M+]+387.2。MS (ESI, m/z): [M+] + 387.2.
1H-NMR(400MHz,CDCl3):δ7.81~7.88(m,2H);7.38~7.51(m,3H);7.16(m,1H);4.14(m,1H);3.52(m,4H);2.70(m,1H);1.81~1.98(m,4H);1.46-1.59(m,4H);1.25~1.44(m,7H)。 1 H-NMR (400MHz, CDCl 3 ): δ7.81~7.88(m, 2H); 7.38~7.51(m, 3H); 7.16(m, 1H); 4.14(m, 1H); 3.52(m, 4H ); 2.70 (m, 1H); 1.81-1.98 (m, 4H); 1.46-1.59 (m, 4H); 1.25-1.44 (m, 7H).
实施例4Example 4
N2气保护下,常温下于500ml三口瓶中加入1-(2-氯丙酰基)-4环己基萘(3,42.9g,0.143mol)和二甲苯(430mL)。搅拌下,向反应液中加入乙二醇(13.3g,0.214mol)和浓硫酸(1.4g,0.014mol)。加毕,在反应瓶上装配分水器,然后加热至回流并保持回流20小时直至反应完全。冷却反应液至室温,加入200mL水淬灭反应,搅拌分离出有机相。有机相用水洗两次(200mL×2)、饱和食盐水(200mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 gas, 1-(2-chloropropionyl)-4cyclohexylnaphthalene (3, 42.9g, 0.143mol) and xylene (430mL) were added into a 500ml three-necked flask at room temperature. Under stirring, ethylene glycol (13.3 g, 0.214 mol) and concentrated sulfuric acid (1.4 g, 0.014 mol) were added to the reaction liquid. After the addition is complete, install a water separator on the reaction bottle, then heat to reflux and maintain reflux for 20 hours until the reaction is complete. Cool the reaction solution to room temperature, add 200 mL of water to quench the reaction, stir and separate the organic phase. The organic phase was washed twice with water (200 mL×2) and once with saturated brine (200 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: Quantitative.
粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.
MS(ESI,m/z):[M+]+345.1。MS (ESI, m/z): [M+] + 345.1.
3.化合物5的合成3. Synthesis of Compound 5
实施例5Example 5
3-氯-2,2-二甲基丙基2-(4-环己基萘基)丙酸酯的合成Synthesis of 3-chloro-2,2-dimethylpropyl 2-(4-cyclohexylnaphthyl)propionate
在N2保护下,向500mL反应瓶中加入2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环(4,55.2g,0.143mol)、氧化锌(2.4g,0.029mol)和甲苯(200mL)。将反应液加热至110℃~130℃并保持在该温度搅拌16小时以上直至反应完全。冷却反应液至室温,加入100mL稀硫酸(2N)淬灭反应,搅拌分离出有机相。有机相用水洗两次(150mL×2)、饱和食盐水(150mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:90%。Under N protection, 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane ( 4, 55.2 g, 0.143 mol), zinc oxide (2.4 g, 0.029 mol) and toluene (200 mL). The reaction solution was heated to 110°C-130°C and kept at this temperature and stirred for more than 16 hours until the reaction was complete. Cool the reaction solution to room temperature, add 100 mL of dilute sulfuric acid (2N) to quench the reaction, stir and separate the organic phase. The organic phase was washed twice with water (150 mL×2) and once with saturated brine (150 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: 90%.
粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.
MS(ESI,m/z):[M+]+387.2。MS (ESI, m/z): [M+] + 387.2.
1H-NMR(400MHz,CDCl3):δ7.60~7.80(m,4H);7.40(m,2H);3.89(m,3H);3.12(m,2H);2.65(m,1H);1.90-1.98(m,4H);1.87(m,1H);1.77(d,3H,J=7.2Hz);1.25-1.51(m,4H);1.26(m,1H);0.81(m,6H)。 1 H-NMR (400MHz, CDCl 3 ): δ7.60~7.80(m, 4H); 7.40(m, 2H); 3.89(m, 3H); 3.12(m, 2H); 2.65(m, 1H); 1.90-1.98(m, 4H); 1.87(m, 1H); 1.77(d, 3H, J=7.2Hz); 1.25-1.51(m, 4H); 1.26(m, 1H); 0.81(m, 6H) .
实施例6Example 6
在N2保护下,向500mL反应瓶中加入2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环(55.2g,0.143mol)、氧化锌(2.4g,0.029mol)、氯化锌(3.9g,0.029mol)和二甲苯(200mL)。将反应液加热至110℃~130℃并保持在该温度搅拌4小时以上直至反应完全。冷却反应液至室温,加入100mL稀盐酸(2N)淬灭反应,搅拌分离出有机相。有机相用水洗两次(150mL×2)、饱和食盐水(150mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:90%。Under N protection, 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane ( 55.2 g, 0.143 mol), zinc oxide (2.4 g, 0.029 mol), zinc chloride (3.9 g, 0.029 mol) and xylene (200 mL). The reaction liquid was heated to 110° C. to 130° C. and kept at this temperature and stirred for more than 4 hours until the reaction was complete. Cool the reaction solution to room temperature, add 100 mL of dilute hydrochloric acid (2N) to quench the reaction, and stir to separate the organic phase. The organic phase was washed twice with water (150 mL×2) and once with saturated brine (150 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: 90%.
粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.
实施例7Example 7
在N2保护下,向500mL反应瓶中加入2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环(55.2g,0.143mol)、醋酸锌(5.4g,0.029mol)和二甲苯(200mL)。将反应液加热至110℃~130℃并保持在该温度搅拌6小时以上直至反应完全。冷却反应液至室温,加入100mL稀盐酸(2N)淬灭反应,搅拌分离出有机相。有机相用水洗两次(150mL×2)、饱和食盐水(150mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:85%。Under N protection, 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane ( 55.2 g, 0.143 mol), zinc acetate (5.4 g, 0.029 mol) and xylene (200 mL). The reaction solution was heated to 110° C. to 130° C. and kept at this temperature and stirred for more than 6 hours until the reaction was complete. Cool the reaction solution to room temperature, add 100 mL of dilute hydrochloric acid (2N) to quench the reaction, and stir to separate the organic phase. The organic phase was washed twice with water (150 mL×2) and once with saturated brine (150 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: 85%.
4.化合物1【维达洛芬】的合成4. Synthesis of Compound 1 [Vidaprofen]
实施例8Example 8
室温下向500mL三口反应瓶中,加入3-氯-2,2-二甲基丙基2-(4-环己基萘基)丙酸酯(5,50.0g,0.13mol)、四氢呋喃(150mL)和甲醇(150mL);搅拌5分钟至固体溶清后,向反应液中加入52mL氢氧化钠水溶液(23%)。得到的反应混合物加热至60℃~70℃反应2小时,直至反应完全。将反应液冷却至室温,减压蒸除有机溶剂,得到的棕色悬浊液用100mL水稀释,然后加入200mL乙酸乙酯萃取。分出有机层,有机相在室温下搅拌1小时,再冷却至0℃~10℃搅拌1小时。过滤,滤饼用乙酸乙酯洗涤(40mL×2)得到白色固体为维达洛芬的钠盐。将得到的白色固体投入100mL稀盐酸(2N)中,搅拌30分钟后过滤,滤饼用水洗两次(40mL×2)得到白色固体,该固体在50℃真空条件下干燥大约16小时得到白色固体,即维达洛芬。收率:~30%,纯度99.7%。To a 500mL three-neck reaction flask at room temperature, add 3-chloro-2,2-dimethylpropyl 2-(4-cyclohexylnaphthyl)propionate (5, 50.0g, 0.13mol), tetrahydrofuran (150mL) and methanol (150 mL); after stirring for 5 minutes until the solid dissolved, 52 mL of aqueous sodium hydroxide solution (23%) was added to the reaction solution. The obtained reaction mixture was heated to 60° C. to 70° C. for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, and the organic solvent was distilled off under reduced pressure. The resulting brown suspension was diluted with 100 mL of water, and then extracted with 200 mL of ethyl acetate. The organic layer was separated, and the organic phase was stirred at room temperature for 1 hour, then cooled to 0°C-10°C and stirred for 1 hour. After filtering, the filter cake was washed with ethyl acetate (40 mL×2) to obtain a white solid which was the sodium salt of vidaprofen. The obtained white solid was put into 100 mL of dilute hydrochloric acid (2N), stirred for 30 minutes, filtered, and the filter cake was washed twice with water (40 mL×2) to obtain a white solid, which was dried at 50°C under vacuum for about 16 hours to obtain a white solid , vidaprofen. Yield: ~30%, purity 99.7%.
MS(ESI,m/z):[M+]+283.4。MS (ESI, m/z): [M+] + 283.4.
1H-NMR(400MHz,DMSO-d6):δ7.73(d,2H,J=8.0Hz);7.65(d,2H,J=17.6Hz);6.84(dd,2H,J1=8.0Hz,J2=18.8Hz);3.69(m,1H);2.64(m,1H);1.80-1.90(m,4H);1.73(m,1H);1.35-1.55(m,4H);1.38(d,3H,J=7.2Hz);1.27(m,1H)。 1 H-NMR (400MHz, DMSO-d 6 ): δ7.73 (d, 2H, J = 8.0Hz); 7.65 (d, 2H, J = 17.6Hz); 6.84 (dd, 2H, J 1 = 8.0Hz , J 2 =18.8Hz); 3.69(m, 1H); 2.64(m, 1H); 1.80-1.90(m, 4H); 1.73(m, 1H); 1.35-1.55(m, 4H); , 3H, J=7.2Hz); 1.27(m, 1H).
实施例9Example 9
室温下向500mL三口反应瓶中,加入3-氯-2,2-二甲基丙基2-(4-环己基萘基)丙酸酯(50.0g,0.13mol)、丙酮(300mL);搅拌5分钟至固体溶清后,向反应液中加入150mL碳酸钾水溶液(30%)。得到的反应混合物加热至60℃~70℃反应2小时,直至反应完全。将反应液冷却至室温,减压蒸除有机溶剂,得到的棕色悬浊液用100mL水稀释,然后加入200mL甲基叔丁基醚萃取。分出有机层,有机相在室温下搅拌1小时,再冷却至0℃~10℃搅拌1小时。过滤,滤饼用甲基叔丁基醚洗涤(40mL×2)得到白色固体为维达洛芬的钠盐。将得到的白色固体投入100mL稀盐酸(2N)中,搅拌30分钟后过滤,滤饼用水洗两次(40mL×2)得到白色固体,该固体在50℃真空条件下干燥大约16小时得到白色固体,即维达洛芬。收率:~30%,纯度99.7%。Add 3-chloro-2,2-dimethylpropyl 2-(4-cyclohexylnaphthyl)propionate (50.0g, 0.13mol) and acetone (300mL) to a 500mL three-necked reaction flask at room temperature; stir After 5 minutes until the solid dissolved, 150 mL of potassium carbonate aqueous solution (30%) was added to the reaction liquid. The obtained reaction mixture was heated to 60° C. to 70° C. for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, and the organic solvent was distilled off under reduced pressure. The obtained brown suspension was diluted with 100 mL of water, and then extracted by adding 200 mL of methyl tert-butyl ether. The organic layer was separated, and the organic phase was stirred at room temperature for 1 hour, then cooled to 0°C-10°C and stirred for 1 hour. After filtering, the filter cake was washed with methyl tert-butyl ether (40 mL×2) to obtain a white solid which was the sodium salt of vidaprofen. The obtained white solid was put into 100 mL of dilute hydrochloric acid (2N), stirred for 30 minutes, filtered, and the filter cake was washed twice with water (40 mL×2) to obtain a white solid, which was dried at 50°C under vacuum for about 16 hours to obtain a white solid , vidaprofen. Yield: ~30%, purity 99.7%.
以上描述和说明了本发明的基本原理、主要特征和优点。本领域的技术人员应该理解,本发明不受上述实施例的限制,上述实施例和说明书中描述的实施方案只是用于说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书界定。The foregoing describes and illustrates the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited by the above examples, and that the above examples and implementations described in the specification are only used to illustrate the principle of the present invention, and without departing from the spirit and scope of the present invention, the present invention The invention also has various changes and improvements, and these changes and improvements all fall within the scope of the claimed invention. The protection scope of the present invention is defined by the appended claims.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110448572.2A CN103183604B (en) | 2011-12-28 | 2011-12-28 | The preparation method of Vedaprofen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110448572.2A CN103183604B (en) | 2011-12-28 | 2011-12-28 | The preparation method of Vedaprofen |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103183604A true CN103183604A (en) | 2013-07-03 |
CN103183604B CN103183604B (en) | 2015-07-29 |
Family
ID=48675084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110448572.2A Active CN103183604B (en) | 2011-12-28 | 2011-12-28 | The preparation method of Vedaprofen |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103183604B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710309A (en) * | 2015-02-05 | 2015-06-17 | 浙江普洛医药科技有限公司 | Synthetic methods of loxoprofen sodium and intermediate thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218473A (en) * | 1977-10-03 | 1980-08-19 | Centre Europeen De Recherches Mauvernay | Derivatives of 4-cyclohexyl-1-naphthalene-acetic acid and their use as drugs |
US4623736A (en) * | 1982-07-09 | 1986-11-18 | The Upjohn Company | Arylalkanoic acid process improvement |
CN1082022A (en) * | 1992-08-14 | 1994-02-16 | 山东新华制药厂 | Molecular transposition prepares the technology of Ibuprofen BP/EP under the catalysis |
-
2011
- 2011-12-28 CN CN201110448572.2A patent/CN103183604B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218473A (en) * | 1977-10-03 | 1980-08-19 | Centre Europeen De Recherches Mauvernay | Derivatives of 4-cyclohexyl-1-naphthalene-acetic acid and their use as drugs |
US4623736A (en) * | 1982-07-09 | 1986-11-18 | The Upjohn Company | Arylalkanoic acid process improvement |
CN1082022A (en) * | 1992-08-14 | 1994-02-16 | 山东新华制药厂 | Molecular transposition prepares the technology of Ibuprofen BP/EP under the catalysis |
Non-Patent Citations (1)
Title |
---|
ORESTE PICCOLO等: "Zinc Salt Catalyzed Rearrangement of Acetals of Optically Active Aryl 1-Chloroethyl Ketones: Synthesis of Optically Active 2-Arylpropionic Acids and Esters", 《J.ORG.CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710309A (en) * | 2015-02-05 | 2015-06-17 | 浙江普洛医药科技有限公司 | Synthetic methods of loxoprofen sodium and intermediate thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103183604B (en) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7323587B2 (en) | Selective estrogen receptor modulators | |
US11465970B2 (en) | Method for synthesis of Roxadustat and intermediate compounds thereof | |
JP5208239B2 (en) | Novel production method of anticancer active tricyclic compounds by alkyne coupling | |
CN102627573B (en) | Synthesis method for 5-aminolevulinic acid hydrochloride | |
CN103755541B (en) | One class chalcone derivative and its production and use | |
CN113603568A (en) | Preparation method of cannabidiol | |
CN108623456A (en) | The preparation method of butylphenyl phthaleine and its pharmaceutical intermediate | |
CN111423394B (en) | Synthesis method of 1,3, 4-oxadiazole heterocyclic compound | |
CN102070586A (en) | Process method for synthesizing 4-site heteroatom-substituted cyclohexenyl halide | |
CN103613568B (en) | The preparation method of a kind of Naphtonone and analogue thereof | |
CN110256451A (en) | A kind of synthetic method of benzofuran simultaneously [2,3-b] quinoline | |
CN101200442A (en) | Process for preparing [1-(mercaptomethyl)cyclopropyl]acetic acid and derivatives thereof | |
CN102267934B (en) | Method for preparing 6-carbomethoxy indolone | |
CN103183604A (en) | Preparation method of vedaprofen | |
CN114736183A (en) | Preparation method of 3-methylflavone-8-carboxylic acid | |
WO2017152539A1 (en) | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound | |
CN113214199B (en) | A kind of synthetic method of benzofuran-3-oxocarboxylate compound | |
CN103420962B (en) | 3-aryl glutaric acid monoester class compound, Preparation Method And The Use | |
JP6256469B2 (en) | Process for the preparation of spiro [2.5] octane-5,7-dione | |
JP5918624B2 (en) | Optically active fluorine-containing 5,6-dihydropyridone derivative and process for producing the same | |
CN101830872A (en) | Synthetic method of 3-hydroxyl benzofuran derivatives | |
CN101397247A (en) | Method for synthesizing raw medicine dihydroindene-1-carboxyl acid for clidabac | |
CN101486643A (en) | Trans naproxen ester, optical isomer thereof, as well as preparation and use thereof | |
CN101456843A (en) | Synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid | |
HU195659B (en) | Process for producing cotarnine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |